LXS196 - CAS# 1874276-76-2 60100 Neurosci Res 86: 270-280

Neurosci Res 86: 270-280

PubMed Central PMCID: PMC4226443

AHU-377 hemicalcium salt

InChiKey: VAVXGGRQQJZYBL-UHFFFAOYSA-N

GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases

LXS196 - CAS# 1874276-76-2 60100 Neurosci Res 86: 270-280LXS196, CAS No. 1874276 76 2, is a potent and orally active protein kinase C inhibitor for the treatment of uveal melanoma. Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine threonine protein kinase overexpressed in certain types of cancer